At one point, the Independence website offered a full 1300-page Evicore "Clinical Guidelines" for labs, 1/2022.
Friday, May 24, 2024
MolDx and NGS / Novitas "Policy Systems" by State
Leaving aside PR and DC, MolDx has 28 states, the NGS MAC 10, and the Novitas FCSO system has 12, totalling 50.
In Google Sheets,
https://docs.google.com/spreadsheets/d/1psX0MUQAWnQawfFE7wmWRiaIew620dUgu3dhh06_4Y0/edit?usp=sharing
Tuesday, May 21, 2024
Adaptive MRD Gapfill 0364U
Code 0364U
Adaptive's new PLA code, 0364U, has a proposed gapfill price of $1823 from MolDx.
Oncology (hematolymphoid neoplasm), genomic sequence analysis using multiplex (PCR) and next-generation sequencing with algorithm, quantification of dominant clonal sequence(s), reported as presence or absence of minimal residual disease (MRD) with quantitation of disease burden, when appropriate. [Eff. 4/2023]
Friday, May 17, 2024
Another example - AI fixes verbose first draft
Another example, same template (which you don't see, it was an actual work).
BACKGROUND
VERBOSE BACKGROUND
The evolution of cancer diagnostics has witnessed a significant breakthrough with the introduction of the OncoGen 5000, a state-of-the-art molecular diagnostic test meticulously crafted by Precision Genomics Inc. This innovative test employs a highly advanced technique known as next-generation sequencing (NGS), which is capable of sequencing DNA at an unprecedented scale and speed. The OncoGen 5000 meticulously analyzes over 800 genes that are known to be associated with various types of cancers, identifying mutations, copy number variations, and gene fusions that are pivotal for accurate cancer diagnosis, prognosis, and therapeutic decision-making. By generating an extensive genomic profile of the tumor, this test provides unparalleled insights into the genetic underpinnings of cancer. The results are compared against a vast and meticulously curated reference database, encompassing genetic data from a diverse cohort of cancer patients worldwide. This comparison not only enhances the accuracy of the diagnosis but also facilitates the development of personalized treatment regimens tailored to the unique genetic makeup of each patient's tumor. The significance of comprehensive genomic profiling in modern oncology is underscored by endorsements from leading medical organizations such as the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN), which advocate for the integration of such advanced diagnostic tools into clinical practice to optimize patient outcomes and advance the field of personalized medicine.
COLLEGE FRESHMAN BACKGROUND
Background of the Test: The OncoGen 5000 test helps doctors understand the genetic changes in cancer cells. It looks at over 800 genes related to cancer to find important mutations and changes. This test uses next-generation sequencing (NGS) to compare a patient's tumor DNA with a large database of genetic information from other cancer patients. This helps doctors diagnose the cancer more accurately and decide on the best treatment plan for each person.
COLLEGE JUNIOR BACKGROUND
Background of the Test: The OncoGen 5000 is an advanced molecular diagnostic test designed to analyze genetic mutations in cancer cells using next-generation sequencing (NGS). It examines over 800 genes related to cancer, identifying mutations, copy number variations, and gene fusions. The test compares the tumor's genetic profile with a reference database containing genetic data from a diverse group of cancer patients. This approach, recommended by ASCO and NCCN, aids in precise cancer diagnosis and personalized treatment planning, enhancing therapeutic outcomes.
PURPOSE AND METHOD
VERBOSE PURPOSE & METHOD
Precision Genomics Inc. has developed the OncoGen 5000 with the primary objective of revolutionizing the precision of cancer diagnosis and the personalization of treatment strategies. This test leverages the capabilities of next-generation sequencing (NGS) to conduct a comprehensive analysis of genetic alterations present in tumor DNA. The workflow begins with the extraction of DNA from a tumor biopsy, followed by NGS, which sequences the DNA to identify genetic mutations, copy number variations, and gene fusions that are critical for understanding the molecular characteristics of the cancer. The extensive data generated from sequencing is processed through a sophisticated bioinformatics pipeline, which includes steps such as data alignment, variant calling, and annotation of genetic alterations. The test's advanced machine learning algorithms then compare the patient's genomic profile to an extensive and meticulously curated reference database. This comparison yields a detailed report that provides insights into the molecular underpinnings of the tumor, highlighting actionable mutations that can inform targeted therapy decisions. The precise genomic profiling enabled by the OncoGen 5000 is essential for tailoring treatment strategies to the individual patient, thereby optimizing therapeutic efficacy and minimizing adverse effects. This approach is in line with the principles of personalized medicine, which aims to provide tailored healthcare solutions based on the unique genetic makeup of each patient.
COLLEGE FRESHMAN PURPOSE & METHOD
Purpose and Methodology of the Test: The OncoGen 5000 test aims to help doctors diagnose and treat cancer more accurately. It works by analyzing genetic changes in tumor DNA using next-generation sequencing (NGS). This involves extracting DNA from the tumor, sequencing it to find mutations, and comparing the results to a large database. This helps doctors understand the specific characteristics of the cancer and choose the best treatment.
COLLEGE JUNIOR PURPOSE & METHOD
Purpose and Methodology of the Test: The OncoGen 5000 is designed to improve cancer diagnosis and treatment by providing a detailed analysis of genetic mutations in tumors using next-generation sequencing (NGS). The process involves extracting DNA from a tumor sample, sequencing the DNA to identify mutations, and comparing the results to a reference database. Advanced algorithms then interpret the data, offering insights into the tumor's molecular profile and guiding personalized treatment strategies. This precise genomic profiling helps doctors make informed decisions about the best treatment options for each patient.
RESOURCES
VERBOSE RESOURCES
The successful implementation of the OncoGen 5000 test necessitates the availability of several critical resources, which are essential for conducting a comprehensive genomic analysis. Initially, a tumor tissue sample must be obtained through a biopsy, and high-quality DNA must be extracted from this sample. The extracted DNA undergoes next-generation sequencing (NGS) using highly specialized sequencing platforms, which are capable of generating vast amounts of genetic data in a relatively short time frame. The sequencing data is then processed through a series of bioinformatics pipelines that include crucial steps such as data alignment, variant calling, and the annotation of genetic mutations. The bioinformatics analysis is further supported by a proprietary reference database that contains genomic information from thousands of cancer patients, ensuring that the comparison is robust and clinically relevant. Additionally, the test requires advanced computational infrastructure to handle the large-scale data processing and the application of machine learning algorithms, which are vital for interpreting the genomic data. The entire workflow is conducted in a certified laboratory equipped with state-of-the-art technology and staffed by personnel with expertise in molecular biology, genetics, and bioinformatics. This combination of resources and expertise is paramount to ensuring the accuracy, reliability, and clinical utility of the OncoGen 5000 test results.
COLLEGE FRESHMAN RESOURCES
Resources Required to Run the Test: To conduct the OncoGen 5000 test, a sample of the tumor tissue is needed. The DNA is extracted from this tissue and analyzed using next-generation sequencing (NGS) technology. The test requires specialized sequencing machines, a large database for comparison, and advanced software to interpret the results. This process is done in a lab with skilled scientists.
COLLEGE JUNIOR RESOURCES
Resources Required to Run the Test: The OncoGen 5000 test requires specific laboratory capabilities, including the extraction of high-quality DNA from tumor samples, next-generation sequencing (NGS) technology for analyzing the DNA, and advanced bioinformatics tools for data interpretation. The test also relies on a comprehensive reference database and sophisticated computational infrastructure. This analysis is conducted in certified laboratories staffed with experts in molecular biology, genetics, and bioinformatics. The combination of these resources ensures the test's accuracy and reliability in providing clinically useful results.
Thursday, April 25, 2024
Nexium sales
According to the search results, Nexium (esomeprazole), a proton pump inhibitor manufactured by AstraZeneca, lost its global patents in May 2014. The key points regarding Nexium's sales are:
- Nexium recorded global sales of $3.87 billion in 2013, including $2.12 billion in the U.S. alone.5
- Nexium was approved in the U.S. in April 2005.5
- AstraZeneca was able to extend Nexium's patent protection through various means, allowing it to maintain blockbuster sales even after the original patent expired.134
- Teva received FDA approval to market a generic version of Nexium in 2015, but the approval was later revoked.3
DO PHARMACISTS BUY BAYER?
Brand preimum
Bronnenberg et al 2015
. In a detailed case study of headache remedies we find that
more informed or expert consumers are less likely to pay extra to buy national brands, with pharmacists
choosing them over store brands only 9 percent of the time, compared to 26 percent of the time for the
average consumer.
Based on the information provided in the search results, the key points regarding branded vs. generic aspirin sales are:
- According to the Harvard study in 1, a 100-tablet package of 325mg Bayer Aspirin costs $6.29, while a 100-tablet package of 325mg CVS store-brand aspirin costs $1.99. This represents a three-fold price premium for the branded Bayer aspirin.
- The same study found that 25% of aspirin sales by volume (and 60% by expenditure) are for national-brand products like Bayer, even though the store-brand alternatives are identical in dosage, directions, and active ingredient.1
- This suggests that around 1 in 4 consumers (or 25%) are willing to pay the higher price for the branded Bayer aspirin, while the remaining 3 in 4 consumers (or 75%) opt for the less expensive store-brand alternative.1
60% could be cut to 20% of total savings of 40% nearly half.
AI Combines CAP TODAY and 360DX Articles on Reimbursement Barriers into One Composite Viewpoint.
In April 2024, Genomeweb [ 360Dx ] and CAP TODAY both had detailed articles on reimbursement headwinds for genomic labs.
Here, as an experiment, I gave the 2 articles to CHAT GPT and asked it to make an integrated report.
An AI Composite. (For experimental purposes only).
360DX
CAP TODAY
https://www.captodayonline.com/billing-headwinds-grow-stronger-for-labs/
###
PLEASE READ BOTH ARTICLES & SUMMARIZE BOTH TOGETHER.
The increasing challenges faced by laboratories in obtaining reimbursement for molecular and complex tests have become a significant focus within the pathology and laboratory industry. Key takeaways from recent discussions and analyses in the "2024 CAP TODAY" and "2024 Genomeweb" articles highlight the growing complexity of billing processes and the impact of regulatory frameworks on laboratory operations.
Prior Authorization and Network Limitations:
Laboratories face growing hurdles in securing prior authorization for tests, especially when out of network with insurers. This problem is exacerbated by narrow networks and the No Surprises Act, which have given insurers more leverage to deny claims or enforce restrictive payer policies .
Reimbursement Challenges for Molecular Tests:
As molecular testing expands, labs report an increasingly Herculean task to get reimbursed. Insurance companies frequently challenge the medical necessity of tests, resulting in extensive documentation requirements and prolonged dispute resolutions, often taking up to six months .
Impact of Regulatory and Market Dynamics:
Changes in market dynamics and regulatory policies, such as the VALID Act and shifts in FDA regulations concerning laboratory-developed tests, pose additional operational challenges. These include the necessity to adapt billing systems to meet new compliance standards while managing payer behaviors that often do not align with these new regulatory frameworks .
Utilization of Technology to Mitigate Billing Issues:
To counteract these challenges, laboratories are increasingly turning to AI and other automated tools to manage the billing cycle more effectively. These technologies help identify claims likely to be reimbursed and prioritize them, reducing the labor needed for claims management and potentially lowering the rate of denied claims .
Strategic Responses to Billing Constraints:
Laboratories are urged to adopt strategic approaches to billing, such as enhancing the accuracy of billing data and improving the efficiency of claims processing. This includes investing in technologies that ensure compliance with payer requirements and engaging in proactive negotiations with insurers to secure better reimbursement terms .
Collaboration and Advocacy:
There is a strong call within the industry for more significant collaboration and advocacy efforts to address these challenges. Laboratories and related organizations are encouraged to band together to influence policy decisions and improve reimbursement practices. This collective action is deemed crucial for sustaining the operational viability of laboratories in the face of financial and regulatory pressures .
In summary, the landscape for pathology and laboratory billing is marked by an increased need for technological integration, strategic management of payer relationships, and vigorous advocacy to navigate the complex reimbursement environment effectively. These efforts are essential to ensure that laboratories can continue to provide necessary testing services without succumbing to financial and operational strains.
###
Describe methods labs may try, that are unlikely to work today, or which used to work and no more. That is, tell us, What "not to do."
In the current landscape of laboratory billing and reimbursement, there are several outdated or ineffective strategies that laboratories may still attempt to use, often resulting in inefficiencies or failures. Here are some methods that laboratories should avoid:
Assuming Standardized Billing Will Suffice:
Previously, a more standardized approach to billing might have been sufficient. However, today, given the specificity and individuality required for molecular and complex tests, this approach is unlikely to meet the diverse requirements of different payers. Each insurance company may have its own unique billing codes and documentation requirements, making a one-size-fits-all billing process ineffective.
Over-Reliance on Manual Processes:
Manual billing and claims management processes are prone to errors and are significantly slower than automated systems. In the past, smaller volumes of complex tests might have allowed for manual management, but with the increase in both the volume and complexity of tests, continuing to rely on manual processes can lead to increased denials and slower reimbursement.
Neglecting Payer-Specific Guidelines:
Ignoring the specific guidelines and requirements of individual payers is a common mistake. Each payer has its own set of rules regarding what is considered medically necessary, the required pre-authorizations, and specific coding instructions. Failure to tailor submissions to each payer’s criteria can lead to repeated denials.
Underestimating the Importance of Pre-Authorizations:
In the past, it might have been possible to secure reimbursement without stringent pre-authorization for certain tests. However, today, insurers are much stricter about pre-authorizations, especially for expensive molecular and complex tests. Not securing pre-authorization or assuming it will be easy to obtain post-hoc can lead to significant reimbursement issues.
Inadequate Follow-Up on Denied Claims:
Previously, the volume and value of individual claims might not have justified extensive follow-up. Today, however, given the high cost associated with many laboratory tests, failing to rigorously pursue denied claims can result in substantial revenue loss. Simply resubmitting claims without understanding or addressing the reason for denial is an ineffective strategy.
Lack of Proactive Communication with Insurers:
A more passive approach might have worked when regulations were less stringent and payer scrutiny was lower. However, in the current regulatory environment, proactive communication with insurers is crucial. Establishing good relationships and maintaining open lines of communication can help address issues before they result in denials.
By avoiding these outdated or ineffective strategies, laboratories can better adapt to the evolving demands of the healthcare billing landscape, enhancing their chances of securing timely and adequate reimbursements for their services.
###
What are three ways the two articles differ?
The two articles, "2024 CAP TODAY" and "2024 Genomeweb," differ in their focus and approach to discussing the challenges faced by laboratories in securing reimbursements. Here are three key differences:
Scope of Focus:
The "2024 CAP TODAY" article tends to have a broader scope, addressing general billing headwinds for laboratories, including issues like prior authorization and the impact of network limitations under the No Surprises Act. It discusses the overall trends in healthcare billing and regulatory changes affecting lab operations.
In contrast, the "2024 Genomeweb" article focuses more specifically on the challenges of obtaining reimbursement for molecular tests. It emphasizes the difficulties labs face due to the complexity of these tests and the rigorous documentation required by insurers to prove medical necessity.
Detail on Regulatory Impact:
The "2024 CAP TODAY" article provides a more detailed discussion on the impact of specific regulatory frameworks such as the VALID Act and changes in FDA regulations concerning laboratory-developed tests (LDTs). It elaborates on how these regulatory changes are reshaping lab operations and billing practices.
On the other hand, the "2024 Genomeweb" article concentrates more on the immediate practical challenges in the billing cycle, particularly the insurer's scrutiny and the lengthy dispute resolution processes, without delving deeply into the broader regulatory context.
Strategic Recommendations:
The "2024 CAP TODAY" article offers strategic advice on dealing with billing constraints, suggesting improvements in data accuracy, claims processing efficiency, and proactive insurer negotiations. It approaches the billing challenges from a strategic management perspective, advising labs on how to adapt their operations comprehensively.
The "2024 Genomeweb" article, while it also touches on strategic responses, tends to emphasize more on the use of technology and automation to mitigate billing issues. It highlights the role of AI and automated tools in managing claims more effectively, focusing on technological solutions to improve reimbursement rates and reduce administrative burdens.
These differences underscore the distinct angles from which each publication addresses the complex issues of laboratory billing and reimbursement, catering to slightly different aspects of the challenges labs face today.
(Please summarize the differences now).
- Scope of Focus: The "2024 CAP TODAY" article discusses broader billing and regulatory challenges for labs, while the "2024 Genomeweb" article specifically focuses on reimbursement issues for molecular tests.
- Detail on Regulatory Impact: "2024 CAP TODAY" provides an in-depth look at how regulatory frameworks like the VALID Act affect lab operations, whereas "2024 Genomeweb" concentrates more on the practical challenges of billing and reimbursement without extensive regulatory context.
- Strategic Recommendations: The "2024 CAP TODAY" article offers broad strategic advice for managing billing constraints, whereas "2024 Genomeweb" emphasizes the use of technology and automation to tackle specific billing issues.
Are there any good essay or analysis questions I missed, that I should have asked, to better understand the implications of the pair of PDF articles?
ChatGPT
Here are a few essay or analysis questions that could deepen your understanding of the implications of the challenges discussed in the two PDF articles regarding laboratory billing and reimbursement:
How do the challenges in reimbursement for molecular tests impact healthcare innovation and patient access to new technologies?
Analyze the potential long-term effects on the development and availability of advanced diagnostic tools when laboratories face significant reimbursement hurdles.
What are the implications of regulatory changes such as the VALID Act on small versus large laboratory operations?
Discuss how varying sizes and types of laboratories might differently experience the impacts of regulatory changes, particularly in terms of operational viability and strategic adaptations.
How does the shifting landscape of insurance policies and payer requirements affect the overall efficiency of healthcare delivery?
Evaluate the broader implications for healthcare systems when laboratories spend extensive resources on billing and compliance rather than on medical research or patient care.
What role does technology play in mitigating the challenges faced by laboratories in securing reimbursements, and what are the potential pitfalls?
Explore the benefits and limitations of relying on technological solutions like AI and automated billing systems to overcome complex billing challenges.
How can laboratories more effectively advocate for favorable policy changes or reimbursement practices with insurers and regulators?
Propose strategies for laboratories to enhance their advocacy efforts and examine the potential outcomes of successful lobbying on reimbursement policies.
Compare and contrast the impacts of insurer-driven reimbursement challenges on public health outcomes in different healthcare systems (e.g., U.S. versus European models).
Analyze how different healthcare frameworks handle reimbursement for complex tests and the subsequent effects on public health and service accessibility.
## These questions could serve as a foundation for essays or in-depth analyses, offering a comprehensive look at the various dimensions and repercussions of the current challenges in laboratory billing and reimbursement as discussed in the articles.
##
Compare and contrast the impacts of insurer-driven reimbursement challenges on public health outcomes in different healthcare systems (e.g., U.S. versus European models).
Analyze how different healthcare frameworks handle reimbursement for complex tests and the subsequent effects on public health and service accessibility.
ChatGPT
The impacts of insurer-driven reimbursement challenges on public health outcomes can be significantly different depending on the healthcare system in question. By comparing the U.S. model, which is largely insurance-based, with European systems that often feature universal healthcare, we can gain insights into how these differences influence access to complex medical tests and overall health outcomes.
U.S. Healthcare System:
Insurance-Driven Reimbursement: In the U.S., reimbursement for medical tests largely depends on insurance company policies. This often means that the availability and speed of diagnostic services can be constrained by the need for pre-authorization and the risk of denials based on insurers' assessments of medical necessity.
Financial Barriers: Patients may face high out-of-pocket costs if tests are not covered, which can delay or prevent access to necessary diagnostic procedures. This financial barrier can lead to disparities in the timeliness and quality of care received by different populations, especially underinsured or uninsured groups.
Impact on Innovation: While the U.S. is known for rapid adoption of innovative medical technologies, reimbursement challenges can stifle the introduction and widespread use of advanced diagnostics if insurers are slow to recognize their value or require extensive evidence of efficacy.
European Healthcare Systems:
Government-Controlled Reimbursement: Many European countries have universal healthcare systems where the government sets reimbursement policies for medical tests. This often allows for more standardized access to diagnostic services across the entire population, reducing variability based on insurance coverage.
Preventive Approach: European systems tend to emphasize preventive care, which includes easier access to diagnostic testing as a means of reducing long-term healthcare costs. This can lead to earlier detection and management of diseases, improving public health outcomes.
Innovation Versus Cost Control: Although European countries also innovate in healthcare, there can be more significant delays in adopting new technologies compared to the U.S. This is partly due to stringent cost-effectiveness evaluations that must justify the expense of new tests and treatments before they are broadly reimbursed.
Comparative Effects on Public Health and Service Accessibility:
Access and Equity: European models generally promote more equitable access to advanced diagnostics regardless of an individual's financial situation, potentially leading to better overall public health outcomes. In contrast, the U.S. system's reliance on private insurance can result in significant disparities in access to care.
Speed of Service: The U.S. might offer faster access to new technologies for those who can afford them, whereas in European systems, while access is more uniformly available, it may take longer for the healthcare system to adopt new technologies.
Public Health Outcomes: The preventive focus in European systems can lead to better long-term public health outcomes by catching diseases earlier and managing them more effectively, reducing overall healthcare costs. Conversely, in the U.S., while the potential for cutting-edge treatment is high, outcomes can vary more widely across different population segments.
In summary, while the U.S. system allows for rapid innovation and can provide high levels of care for those with adequate insurance, the European model offers more consistent care across the population, potentially leading to better average outcomes at the cost of slower adoption of new technologies. Each system presents unique challenges in terms of how reimbursements for complex tests are managed and how these management strategies affect public health and service accessibility.
###
How can laboratories more effectively advocate for favorable policy changes or reimbursement practices with insurers and regulators?
Propose strategies for laboratories to enhance their advocacy efforts and examine the potential outcomes of successful lobbying on reimbursement policies.
ChatGPT
Laboratories can play a crucial role in shaping the policies and practices that affect their operations and the broader healthcare landscape. Effective advocacy for favorable policy changes or reimbursement practices involves a multifaceted approach that encompasses strategic communication, coalition building, and evidence-based persuasion. Here are several strategies laboratories could employ to enhance their advocacy efforts:
1. Forming Strategic Alliances
Collaborate with Industry Associations: Joining forces with industry groups like the American Clinical Laboratory Association or similar organizations in other countries can amplify the voices of individual labs. These associations often have established channels for lobbying and can coordinate efforts to push for changes that benefit the entire sector.
Partner with Healthcare Providers: Collaborations with hospitals and clinics that rely on lab services can create a united front, demonstrating to insurers and regulators how lab services are integral to patient care and the broader healthcare ecosystem.
2. Utilizing Data and Research
Gather Impact Data: Collect and present data on how current reimbursement policies affect patient outcomes, service accessibility, and healthcare costs. This could include case studies that showcase the benefits of rapid and unfettered access to lab tests.
Economic Analysis: Provide cost-benefit analyses to show how effective lab testing can reduce overall healthcare expenditures by preventing disease progression and reducing the need for more expensive treatments later on.
3. Engaging in Direct Lobbying
Hire Expert Lobbyists: Engaging professionals with experience in healthcare policy can help navigate the complexities of legislative and regulatory environments. These experts can craft compelling arguments and engage directly with key policymakers.
Testify at Hearings: Offering expert testimony during regulatory or legislative hearings can put a spotlight on critical issues facing the laboratory industry and influence public policy directly.
4. Public Campaigns and Awareness
Educational Campaigns: Launch campaigns to educate the public, policymakers, and other stakeholders about the critical role of laboratories in healthcare. Increased public awareness can lead to greater support for policy changes.
Media Engagement: Utilize media outlets to highlight studies, success stories, and the challenges of current reimbursement models, thus shaping public opinion and increasing pressure on decision-makers.
5. Continuous Policy Monitoring and Engagement
Stay Informed on Changes: Keeping abreast of regulatory changes and proposed legislation allows laboratories to react swiftly and adjust their advocacy strategies accordingly.
Ongoing Dialogue: Maintain a continuous dialogue with insurers and regulatory bodies, ensuring that laboratories are considered a vital stakeholder in discussions about healthcare policy.
Potential Outcomes of Successful Advocacy
Improved Reimbursement Rates: Effective advocacy can lead to better reimbursement practices, ensuring that labs are compensated adequately for their services, which in turn supports financial stability and investments in advanced technologies.
Enhanced Patient Care: By securing favorable policies, labs can ensure that their tests remain accessible and affordable, leading to earlier diagnosis and treatment of diseases and improving overall health outcomes.
Stimulation of Innovation: When labs are not constrained by restrictive reimbursement policies, they are more likely to invest in research and development, leading to innovative testing techniques that can transform healthcare practices.
Through these strategic advocacy efforts, laboratories can effectively influence policy and regulatory environments, which is essential for maintaining their operational viability and continuing to provide crucial services that enhance public health.
Subscribe to:
Posts (Atom)